The Hindu Business Line : Dr Reddy's launches new drug

Hyderabad, May 29 Dr Reddy's Laboratories Ltd, the Hyderabad-based pharma major, has launched Atocor-R (Atorvastatin + Ramipril) for the domestic market. It is the first such combination to be approved by the Drug Controller General of India (DCGI) and has completed a multicentre clinical trial data on Indian patients. Atocor-R is used in the treatment of patients with both essential hypertension and hypercholesterolernia, according to a press release from Dr Reddy's. It is available in two fixed dose combinations of Atocor-R 2.5 (Atorvastatin 10mg + Ramipril 2.5mg) and Atocor-R 5 (Atorvastatin 10mg + Ramipril 5 mg) and comes is packs of 10. Atorvastatin market is currently valued at Rs 300 crore growing at over 34 per cent annually. Ramipril's market is about Rs 145 crore growing at over 15 per cent annually. - Our Bureau

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Creative Portico to focus on ‘health’ bedding products

HP to launch more ‘lifestyle computing’ range of laptops

Wipro Lighting wins trademark infringement case

Mistral to represent Altium in India

London is world’s most expensive office market: CBRE

India, an emerging TV market for football: UEFA

Philips’ India-centric products see demand in overseas markets

Top-level promotions in Turner India

Asia Pacific Breweries launches Tiger Beer, more to follow

Dr Reddy's launches new drug